Preferential suppression of lymphocyte proliferation by mycophenolic acid and predicted long-term effects of mycophenolate mofetil in transplantation.
Allison
A C
AC
Dawa Corporation, Belmont, Calif.
Eugui
E M
EM
D000818:Animals; D001402:B-Lymphocytes / Q000276:immunology; D015815:Cell Adhesion Molecules / Q000096:biosynthesis; D002455:Cell Division / Q000187:drug effects; D002472:Cell Transformation, Viral; D002648:Child; D016572:Cyclosporine / Q000494:pharmacology; D005643:Fucose / Q000378:metabolism; D006084:Graft Rejection / Q000276:immunology; D004854:Herpesvirus 4, Human / Q000235:genetics; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use* / Q000633:toxicity; D008213:Lymphocyte Activation / Q000187:drug effects*; D008358:Mannose / Q000378:metabolism; D009131:Muscle, Smooth, Vascular / Q000166:cytology / Q000187:drug effects; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D014181:Transplantation Immunology
D015815:Cell Adhesion Molecules; D007166:Immunosuppressive Agents; D005643:Fucose; D016572:Cyclosporine; D009173:Mycophenolic Acid; D008358:Mannose